Siemens Medical Systems has appointed Barbara Franciose as groupvice president of its nuclear medicine group in Hoffman Estates,IL. Franciose replaces Thomas Cafarella, who led the divisionfor two years (SCAN 7/14/93). Franciose is a Siemens veteran
Siemens Medical Systems has appointed Barbara Franciose as groupvice president of its nuclear medicine group in Hoffman Estates,IL. Franciose replaces Thomas Cafarella, who led the divisionfor two years (SCAN 7/14/93).
Franciose is a Siemens veteran who previously headed the vendor'sangiography division, which is also located at the nuclear group'sHoffman Estates facility. She has an engineering background, withdegrees from the University of Illinois and Marquette University.
Franciose's appointment comes amid other recent personnel changesat Siemens' nuclear medicine group, including the appointmentof Randy Weatherhead as vice president of sales and marketing(SCAN 9/27/95).
Siemens has been trying to rebuild its once-dominant positionin the nuclear medicine industry, but has found the going toughdue to the slumping gamma camera market and stiff competitionfrom other vendors.
In other Siemens personnel moves, Wolfgang Kroll has been namedexecutive vice president of business administration and financeat the vendor's Iselin, NJ, headquarters. Paul Mathews was namedgroup vice president of the firm's electromedical group.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.